Watch the recording to hear about:

• The impact of the EU pharmaceutical proposal on the R&D landscape in Europe, with specific examples from Bayer.
• Existing obstacles to ensuring equal access to medicines throughout Europe and potential solutions, such as EFPIA's proposal for equity-based tier pricing, meaning pricing based on what each country can afford.
• Regulatory changes that have the potential to enhance Europe's competitiveness. 

Stefan Oelrich is member of the Board of Management of Bayer AG and head of the Pharmaceuticals Division.